用法用量 |
Single-agent therapy
IV infusion(over 60 minutes)
3 mg/kg every 2 weeks or 240mg every 2 weeks or 480mg every 4 weeks
Combination therapy
Melanoma, unresectable or metastatic:
1mg/kg every 3 weeks or 3mg/kg every 2 weeks or 240mg every 2 weeks or 480mg every 4 weeks
Non–small cell lung cancer, resectable, neoadjuvant therapy
360mg once every 3 weeks
Non–small cell lung cancer, metastatic, with PD-L1 expression
3mg/kg every 2 weeks or 360mg every 3 weeks
Non–small cell lung cancer, metastatic, relapsed or refractory
360mg every 3 weeks
Mesothelioma, pleural , unresectable
3mg/kg every 2 weeks or 360mg every 3 weeks
Non–small cell lung cancer, metastatic or recurrent
360 mg once every 3 weeks
Renal cell carcinoma, advanced
3mg/kg every 3 weeks or 240mg every 2 weeks or 480mg every 4 weeks
Urothelial carcinoma, unresectable or metastatic
360mg every 3 weeks or 240mg every 2 weeks or 480mg every 4 weeks
Gastric cancer or gastroesophageal junction cancer
360mg every 3 weeks or 240mg every 2 weeks
Colorectal cancer, unresectable or metastatic, microsatellite instability high or mismatch repair deficient
240mg every 3 weeks with ipilmumab or 240mg every 2 weeks or 480mg every 4 weeks
Esophageal cancer, squamous cell carcinoma
240mg every 2 weeks or 480mg every 4 weeks or 3mg/kg every 2 weeks or 360mg every 3 weeks
Hepatocellular carcinoma
1mg/kg every 3 weeks or 240mg every 2 weeks or 480mg every 4 weeks |